|
 The companies did not disclose the financial details of the
agreement, but said terms were based on the volume of doses and the
timing of the delivery.
The United States has signed a similar deal with Pfizer and BioNtech
for 100 million doses for nearly $2 billion, which amounts to a $39
price tag for what is likely to be a two dose treatment course.
There is no current vaccine for COVID-19. The disease has claimed
670,000 lives and upended economies, and there are over 150 vaccines
in various stages of development against the still fast-spreading
virus.
BioNTech and Pfizer on Monday began a large, late-stage trial of
their vaccine candidate to demonstrate its efficacy.
[to top of second column] |
Daiichi Sankyo Co <4568.T> is in discussions to provide supplies of
a potential coronavirus vaccine being developed by AstraZeneca Plc <AZN.L>
and the University of Oxford for use in Japan.
Assuming clinical success of the vaccines, Pfizer and BioNtech said
they are on track to seek regulatory review for the vaccine as early
as October.
(Reporting by Ismail Shakil and Manas Mishra in Bengaluru; Editing
by Bernard Orr)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
